The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells

Biochemical and Biophysical Research Communications

Volumn 380, Issue 3, 2009, Pages 638-643

  Vazquez Martin, Alejandro ^a,b   Oliveras Ferraros, Cristina ^a,b   Bernadó, Luis ^a,b   López Bonet, Eugeni ^a,b   Menendez, Javier A ^a,b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

Author keywords

Cancer; Cell cycle; Chromosomal passenger protein; Cytokinesis; Mitosis; mTOR

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; SERINE;

ANAPHASE; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIVISION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINESIS; CYTOPLASM; DAUGHTER CELL; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOPHASE;

CARRIER PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; HUMANS; NEOPLASMS; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SERINE;

MAMMALIA;

EID: 60549112707     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.01.153     Document Type: Article

References (22)

1. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348
2. Easton J.B., and Houghton P.J. mTOR and cancer therapy. Oncogene 25 (2006) 6436-6446
3. Rubio-Viqueira B., and Hidalgo M. Targeting mTOR for cancer treatment. Curr. Opin. Investig. Drugs 7 (2006) 501-512
4. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
5. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
6. Albanell J., Dalmases A., Rovira A., and Rojo F. mTOR signalling in human cancer. Clin. Transl. Oncol. 9 (2007) 484-493
7. Fasolo A., and Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs 17 (2008) 1717-1734
8. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., and Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7 (2008) 11-20
9. Yonezawa K., Yoshino K.I., Tokunaga C., and Hara K. Kinase activities associated with mTOR. Curr. Top. Microbiol. Immunol. 279 (2004) 271-282
10. Lawrence J.C., Lin T.A., McMahon L.P., and Choi K.M. Modulation of the protein kinase activity of mTOR. Curr. Top. Microbiol. Immunol. 279 (2004) 199-213
11. Yaba A., Bianchi V., Borini A., and Johnson J. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells. Reprod. Sci. 15 (2008) 128-138
12. Carraway H., and Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 6 (2004) 219-224
13. Lu C.H., Wyszomierski S.L., Tseng L.M., Sun M.H., Lan K.H., Neal C.L., Mills G.B., Hortobagyi G.N., Esteva F.J., and Yu D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res. 13 (2007) 5883-5888
14. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., and Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68 (2008) 8022-8030
15. Vagnarelli P., and Earnshaw W.C. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 113 (2004) 211-222
16. Vader G., Medema R.H., and Lens S.M. The chromosomal passenger complex: guiding Aurora-B through mitosis. J. Cell Biol. 173 (2006) 833-837
17. Ruchaud S., Carmena M., and Earnshaw W.C. Chromosomal passengers: conducting cell division. Nat. Rev. Mol. Cell Biol. 8 (2007) 798-812
18. Carmena M. Cytokinesis: the final stop for the chromosomal passengers. Biochem. Soc. Trans. 36 (2008) 367-370
19. Lee Y.M., and Kim W. Kinesin superfamily protein member 4 (KIF4) is localized to midzone and midbody in dividing cells. Exp. Mol. Med. 36 (2004) 93-97
20. Kurasawa Y., Earnshaw W.C., Mochizuki Y., Dohmae N., and Todokoro K. Essential roles of KIF4 and its binding partner PRC1 in organized central spindle midzone formation. EMBO J. 23 (2004) 3237-3248
21. D'Avino P.P., Savoian M.S., and Glover D.M. Cleavage furrow formation and ingression during animal cytokinesis: a microtubule legacy. J. Cell Sci. 118 (2005) 1549-1558
22. Canman J.C., Lewellyn L., Laband K., Smerdon S.J., Desai A., Bowerman B., and Oegema K. Inhibition of Rac by the GAP activity of centralspindlin is essential for cytokinesis. Science 322 (2008) 1543-1546